A pH-Sensitive Prodrug Nanocarrier Based on Diosgenin for Doxorubicin Delivery to Efficiently Inhibit Tumor Metastasis
Authors:
Open Access
- 1 September 2020
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 6545-6560
Abstract
Background: The metastasis, one of the biggest barriers in cancer therapy, is the leading cause of tumor deterioration and recurrence. The anti.-metastasis has been considered as a feasible strategy for clinical cancer management. It is well known that diosgenin could inhibit tumor metastasis and doxorubicin (DOX) could induce tumor apoptosis. However, their efficient delivery remains challenging. Purpose: To address these issues, a novel pH-sensitive polymer-prodrug based on diosgenin nanoparticles (NPs) platform was developed to enhance the efficiency of DOX delivery (DOX/NPs) for synergistic therapy of cutaneous melanoma, the most lethal form of skin cancer with high malignancy, early metastasis and high mortality. Methods and Results: The inhibitory effect of DOX/NPs on tumor proliferation and migration was superior to that of NPs or free DOX. What is more, DOX/NPs could combine mitochondria-associated metastasis and apoptosis with unique internalization pathway of carrier to fight tumors. In addition, biodistribution experiments proved that DOX/NPs could efficiently accumulate in tumor sites through enhancing permeation and retention (EPR) effect compared with free DOX. Importantly, the data from in vivo experiment revealed that DOX/NPs without heart toxicity significantly inhibited tumor metastasis by exerting synergistic therapeutic effect, and reduced tumor volume and weight by inducing apoptosis. Conclusion: The nanocarrier DOX/NPs with satisfying pharmaceutical characteristics based on the establishment of two different functional agents is a promising strategy for synergistically enhancing effects of cancer therapy.Keywords
This publication has 54 references indexed in Scilit:
- Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil PhosphoribosyltransferaseMolecular Cancer Therapeutics, 2011
- Strategies in the design of nanoparticles for therapeutic applicationsNature Reviews Drug Discovery, 2010
- Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cellsCancer Letters, 2010
- Cyclooxygenase-2 and 5-lipoxygenase pathways in diosgenin-induced apoptosis in HT-29 and HCT-116 colon cancer cellsInternational Journal of Oncology, 2010
- Metastasis: a therapeutic target for cancerNature Clinical Practice Oncology, 2008
- pH-Triggered Reversible “Stealth” Polycationic MicellesBiomacromolecules, 2007
- Metastasis: a question of life or deathNature Reviews Cancer, 2006
- Diabetes and mitochondrial function: Role of hyperglycemia and oxidative stressToxicology and Applied Pharmacology, 2006
- A new role for GABA: inhibition of tumor cell migrationTrends in Pharmacological Sciences, 2003
- The Bcl2 family: regulators of the cellular life-or-death switchNature Reviews Cancer, 2002